<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43433">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01746225</url>
  </required_header>
  <id_info>
    <org_study_id>IBCSG 42-12/BIG 2-12</org_study_id>
    <secondary_id>2012-003058-10</secondary_id>
    <nct_id>NCT01746225</nct_id>
  </id_info>
  <brief_title>Schedules of Nab-Paclitaxel in Metastatic Breast Cancer</brief_title>
  <acronym>SNAP</acronym>
  <official_title>A Randomized Phase II Study Evaluating Different Schedules of Nab-Paclitaxel in Metastatic Breast Cancer (SNAP Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Breast Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Breast Cancer Study Group</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Ireland: Irish Medicines Board</authority>
    <authority>Slovenia: Agency for Medicinal Products - Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Longer first line chemotherapy duration has recently been associated with a modest, but
      significant improvement in overall survival and a clinically meaningful and statistically
      significant improvement in progression-free survival, in metastatic breast cancer patients.
      Prolonging chemotherapy until disease progression, however, must be weighed against the
      detrimental effects of continuous chemotherapy delivery. The SNAP trial seeks to improve the
      tolerability of prolonged chemotherapy administration strategy by studying alternative
      treatment schedules, while preserving and possibly improving treatment efficacy in this
      disease setting.

      The availability of a new nanoparticle albumin-bound taxane, nab-Paclitaxel (AbraxaneÂ®),
      represents an opportunity to test this hypothesis. Nab-Paclitaxel has been developed in an
      attempt to reduce the toxicity associated with standard taxane administration (caused by the
      use of chemical solvents) while increasing antitumor efficacy.

      The SNAP randomized phase II trial evaluates three schedules of nab-Paclitaxel as prolonged
      chemotherapy administration strategy. Each of three arms will be compared to a historical
      reference of seven-month median progression-free survival (PFS) based on the most recent
      trial with docetaxel as control arm to determine whether any of the three arms are worthy of
      further investigation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy of nab-Paclitaxel schedules</measure>
    <time_frame>At the end of the third induction cycle and during maintenace nab-Paclitaxel every three months until PD (an expected average of nine months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Disease response and progression will be evaluated according to the revised Response Evaluation Criteria in Solid Tumors (RECIST V 1.1) Patients may have measurable or non-measurable disease. CT can is the method to measure lesion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability, feasibility, disease response and OS of nab-Paclitaxel schedules</measure>
    <time_frame>Targeted AEs at the end of each cycle and  hematology days  1, 8, 15, 22 according to treatment arm</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determination of targeted adverse events (AE), performance status, hematological/ biochemical examinations and physical exams are used to evaluate tolerability and feasibility, vital signs for overall survival (OS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>QL self-assessment once each months until PD (maximal twelve months, expected average of nine months) and at end-of-treatment visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>To explore the changes in quality of life (QL) over time until treatment discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic biomarker analysis</measure>
    <time_frame>SPARC and caveolin expressions will be determined in FFPE (formalin fixed paraffin embedded) samples from primary tumor (obtained 14 days prior to randomization) and from FFPE sample of metastatic biopsy at PD (an expected average of nine months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>To investigate the prognostic role of putative markers (SPARC and caveolin) and assess any change in the expression of SPARC and caveolin between primary and the metastatic sites.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Metastatic Breast Cancer.</condition>
  <arm_group>
    <arm_group_label>nab-Paclitaxel 150 mg/m2 days 1,15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A: Induction nab-Paclitaxel 150 mg/m2 on days 1,8,15 every 28 days for 3 cycles  followed by maintenance nab-Paclitaxel  150 mg/m2 administered on days 1, 15 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nab-Paclitaxel 100 mg/m2 days 1,8,15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B: Induction nab-Paclitaxel 150 mg/m2 on days 1,8,15 every 28 days for 3 cycles  followed by maintenance nab-Paclitaxel  100 mg/m2 administered on days 1, 8, 15 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nab-Paclitaxel 75 mg/m2 days 1,8,15,22</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm C: Induction nab-Paclitaxel 150 mg/m2 on days 1,8,15 every 28 days for 3 cycles  followed by maintenance nab-Paclitaxel  75 mg/m2 administered on days 1, 8, 15, 22 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-Paclitaxel</intervention_name>
    <description>Induction phase: 3 cycles of nab-Paclitaxel days 1, 8, 15. Maintenance phase with three maintenance schedules of nab-Paclitaxel (same total dose per cycle,  different number of administrations)</description>
    <arm_group_label>nab-Paclitaxel 150 mg/m2 days 1,15</arm_group_label>
    <arm_group_label>nab-Paclitaxel 100 mg/m2 days 1,8,15</arm_group_label>
    <arm_group_label>nab-Paclitaxel 75 mg/m2 days 1,8,15,22</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed HER2-negative metastatic (stage IV) breast
             cancer.

          -  Measurable or non-measurable, but radiologically evaluable, disease according to
             RECIST 1.1 criteria.

          -  Female aged 18 years or older.

          -  Life expectancy &gt; 3 months.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

          -  Either ER-positive or ER-negative disease. Patients with ER-positive disease must be
             endocrine resistant, defined as having failed at least one prior endocrine therapy
             for breast cancer, or must be candidates for first-line chemotherapy.

          -  If previously treated with a taxane or anthracycline in the neoadjuvant or adjuvant
             setting, the period from end of treatment to disease recurrence must have been &gt; 12
             months (&gt; 365 days).

          -  Radiation therapy, if given and regardless of site, must be completed at least 2
             weeks prior to randomization.

          -  Normal hematologic status.

          -  Normal renal function.

          -  Normal liver function.

          -  Normal cardiac function.

          -  Women of childbearing potential: documented negative pregnancy test within 2 weeks
             prior to randomization, and acceptable birth control during the duration of the trial
             therapy and for a period of 6 months following the last administration of study drug.

          -  Written Informed Consent (IC) must be signed and dated by the patient and the
             Investigator prior to randomization.

          -  Completed baseline Quality of Life Form.

          -  The patient has been informed of and agrees to data transfer and handling, in
             accordance with national data protection guidelines.

          -  Availability of an formalin fixed paraffin embedded (FFPE) block from the primary
             tumor (breast lesion) for submission to central pathology review and for
             translational research.

          -  Written consent to pathology material submission, signed and dated by the patient and
             the Investigator prior to randomization.

        Exclusion Criteria:

          -  Any prior chemotherapy for metastatic breast cancer.

          -  Presence of central nervous system (CNS) metastasis.

          -  Peripheral neuropathy grade 2 or higher (CTCAE version 4).

          -  Significant uncontrolled cardiac disease (i.e. unstable angina, recent myocardial
             infarction within prior 6 months), patients classified as having a New York Heart
             Association (NYHA) class III or IV congestive heart failure.

          -  Pregnant or lactating.

          -  Prior history of non-breast malignancy (except for adequately controlled basal cell
             carcinoma of the skin, carcinoma in situ of the cervix, in situ carcinoma of the
             bladder).

          -  Any concurrent condition which in the Investigator's opinion makes it inappropriate
             for the patient to participate in the trial or which would jeopardize compliance with
             the protocol.

          -  Contraindications or known hypersensitivity to the study medication or excipients.

          -  The use of any anti-cancer investigational agents within 30 days prior to expected
             start of trial treatment.

          -  Inability or unwillingness to abide by the study protocol or cooperate fully with the
             Investigator.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandra Gennari, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Medical Oncology, E.O. Galliera, Genoa, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guy Jerusalem, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Sart Tilman and University of LiÃ¨ge, LiÃ¨ge, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Sart Tilman, Medical Oncology</name>
      <address>
        <city>LiÃ¨ge</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy Jerusalem, MD, PhD</last_name>
      <phone>+32 43 667 664</phone>
      <email>g.jerusalem@chu.ulg.ac.be</email>
    </contact>
    <investigator>
      <last_name>Guy Jerusalem, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR de la Citadelle, Oncology-Haematology Unit</name>
      <address>
        <city>LiÃ¨ge</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Paul Salmon, Dr</last_name>
      <phone>+32 42 25 64 45</phone>
      <email>jean.paul.salmon@chrcitadelle.be</email>
    </contact>
    <investigator>
      <last_name>Jean Paul Salmon, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Peltzer-La Tourelle, Department of Clinical Cancerology</name>
      <address>
        <city>Verviers</city>
        <zip>4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annelore Barbeaux, MD</last_name>
      <phone>+32 87 21 94 83</phone>
      <email>annelore.barbeaux@chplt.be</email>
    </contact>
    <investigator>
      <last_name>Annelore Barbeaux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryan Hennessy</last_name>
      <email>bryan.hennessy@hse.ie</email>
    </contact>
    <investigator>
      <last_name>Bryan Hennessy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St James's Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Kennedy</last_name>
      <email>jkennedy@stjames.ie</email>
    </contact>
    <investigator>
      <last_name>John Kennedy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice Walshe</last_name>
      <email>janice.walshe@amnch.ie</email>
    </contact>
    <investigator>
      <last_name>Janice Walshe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Private Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Kelly</last_name>
      <email>ckelly@mater.ie</email>
    </contact>
    <investigator>
      <last_name>Catherine Kelly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Kelly</last_name>
      <email>ckelly@mater.ie</email>
    </contact>
    <investigator>
      <last_name>Catherine Kelly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid-Western Regional Hospital</name>
      <address>
        <city>Limerick</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Coate</last_name>
      <email>lindae.coate@hse.ie</email>
    </contact>
    <investigator>
      <last_name>Linda Coate</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waterford Regional Hospital</name>
      <address>
        <city>Waterford</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam O'Connor</last_name>
      <email>Miriam.OConnor2@hse.ie</email>
    </contact>
    <investigator>
      <last_name>Miriam O'Connor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera SS Antonio e Biagio</name>
      <address>
        <city>Alessandria</city>
        <zip>15121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierluigi Piovano</last_name>
      <email>plpiovano@ospedale.al.it</email>
    </contact>
    <investigator>
      <last_name>Pierluigi Piovano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi</name>
      <address>
        <city>Biella</city>
        <zip>13900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice Giacobino</last_name>
      <email>alice.giacobino@poloncologico.org</email>
    </contact>
    <investigator>
      <last_name>Alice Giacobino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;B. Ramazzini&quot;</name>
      <address>
        <city>Carpi/ Modena</city>
        <zip>41012</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabrizio Artioli</last_name>
      <email>f.artioli@ausl.mo.it</email>
    </contact>
    <investigator>
      <last_name>Fabrizio Artioli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>E.O. Ospedali Galliera</name>
      <address>
        <city>Genova</city>
        <zip>16128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandra Gennari</last_name>
      <email>alessandra.gennari@galliera.it</email>
    </contact>
    <investigator>
      <last_name>Alessandra Gennari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia (IEO)</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Colleoni</last_name>
      <email>marco.colleoni@ieo.it</email>
    </contact>
    <investigator>
      <last_name>Marco Colleoni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Salvatore Maugeri</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lorenzo Pavesi</last_name>
      <email>lorenzo.pavesi@fsm.it</email>
    </contact>
    <investigator>
      <last_name>Lorenzo Pavesi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi di Roma La Sapienza</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Naso</last_name>
      <email>giuseppe.naso@uniroma1.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Naso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Armando Santoto</last_name>
      <email>armando.santoro@humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Armando Santoro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS MultiMedica</name>
      <address>
        <city>Sede di Castellanza</city>
        <zip>21053</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisa Gallerani</last_name>
      <email>Elisa.Gallerani@multimedica.it</email>
    </contact>
    <investigator>
      <last_name>Elisa Gallerani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Osp. Universitaria di Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabio Puglisi</last_name>
      <email>fabio.puglisi@uniud.it</email>
    </contact>
    <investigator>
      <last_name>Fabio Puglisi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Borstnar</last_name>
      <email>sborstnar@onko-i.si</email>
    </contact>
    <investigator>
      <last_name>Simona Borstnar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Rochlitz</last_name>
      <email>Christoph.Rochlitz@usb.ch</email>
    </contact>
    <investigator>
      <last_name>Christoph Rochlitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Oncologico della Svizzera Italiana</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivia Pagani</last_name>
      <email>olivia.pagani@ibcsg.org</email>
    </contact>
    <investigator>
      <last_name>Olivia Pagani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsspital/ Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuela Rabaglio</last_name>
      <email>manuela.rabaglio@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Manuela Rabaglio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalzentrum Biel</name>
      <address>
        <city>Biel</city>
        <zip>2501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Borner</last_name>
      <email>markus.borner@szb-chb.ch</email>
    </contact>
    <investigator>
      <last_name>Markus Borner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital GraubÃ¼nden</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger von Moos</last_name>
      <email>roger.vonmoos@ksgr.ch</email>
    </contact>
    <investigator>
      <last_name>Roger von Moos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Aebi</last_name>
      <email>stefan.aebi@onkologie.ch</email>
    </contact>
    <investigator>
      <last_name>Stefan Aebi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ursula Hasler-Strub</last_name>
      <email>ursula.hasler-strub@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Ursula Hasler-Strub</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkologiezentrum Thun-Berner Oberland</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rauch Daniel</last_name>
      <email>daniel.rauch@spitalstsag.ch</email>
    </contact>
    <investigator>
      <last_name>Daniel Rauch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Witerthur</city>
        <zip>8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Mueller</last_name>
      <email>andreas.mueller@ksw.ch</email>
    </contact>
    <investigator>
      <last_name>Andreas Mueller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Slovenia</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Chia SK, Speers CH, D'yachkova Y, Kang A, Malfair-Taylor S, Barnett J, Coldman A, Gelmon KA, O'reilly SE, Olivotto IA. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007 Sep 1;110(5):973-9.</citation>
    <PMID>17647245</PMID>
  </reference>
  <reference>
    <citation>Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer. 2005 Oct 15;104(8):1742-50.</citation>
    <PMID>16149088</PMID>
  </reference>
  <reference>
    <citation>Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, Kabbaj O, Spano JP, Marsiglia H, Rouzier R, Delaloge S, Spielmann M. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol. 2004 Aug 15;22(16):3302-8.</citation>
    <PMID>15310773</PMID>
  </reference>
  <reference>
    <citation>Dawood S, Broglio K, Gonzalez-Angulo AM, Buzdar AU, Hortobagyi GN, Giordano SH. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol. 2008 Oct 20;26(30):4891-8. Epub 2008 Aug 25.</citation>
    <PMID>18725649</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 30, 2013</lastchanged_date>
  <firstreceived_date>November 28, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic</keyword>
  <keyword>Breast</keyword>
  <keyword>Cancer</keyword>
  <keyword>HER2-negative Stage IV</keyword>
  <keyword>No previous chemotherapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
